The estimated Net Worth of Andrew Gengos is at least $52 mil dollars as of 3 September 2024. Andrew Gengos owns over 1,272 units of Athira Pharma stock worth over $47,791 and over the last 7 years Andrew sold ATHA stock worth over $4,240.
Andrew has made over 4 trades of the Athira Pharma stock since 2023, according to the Form 4 filled with the SEC. Most recently Andrew sold 1,272 units of ATHA stock worth $725 on 3 September 2024.
The largest trade Andrew's ever made was buying 65,012 units of Athira Pharma stock on 2 June 2023 worth over $191,785. On average, Andrew trades about 10,312 units every 57 days since 2017. As of 3 September 2024 Andrew still owns at least 97,532 units of Athira Pharma stock.
You can see the complete history of Andrew Gengos stock trades at the bottom of the page.
Andrew's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Over the last 4 years, insiders at Athira Pharma have traded over $100,296 worth of Athira Pharma stock and bought 5,411,219 units worth $62,123,025 . The most active insiders traders include Advisors Llcperceptive Life..., Investments, Lpwong Roderic..., eJoseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of $62,547. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth $725.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma executives and other stock owners filed with the SEC include: